Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids - PubMed (original) (raw)
Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids
C Ferran et al. Transplantation. 1990 Oct.
Abstract
In keeping with the in vitro mitogenic properties of anti-CD3 MoAbs, the first injections of anti-CD3 are invariably responsible for an in vivo cellular activation. This activation induces a massive cytokine release in the circulation (TNF, IFN gamma, IL-2, IL-6, and IL-3). Paralleling this release, a severe clinical reaction occurs in OKT3-treated patients and in 145 2C11-treated mice. Corticosteroids both in vitro and in vivo inhibit the production of several cytokines involved in the anti-CD3 reaction. A single 1 mg hydrocortisone dose was administered to 145 2C11-treated mice according to different kinetics schedules. When given 1 hr prior to the anti-CD3 MoAb, hydrocortisone exerted a beneficial effect on the mouse physical reaction. Hypothermia was totally abrogated at the 4-hr time point. Diarrhea decreased by 50%. Hypomotility improved although not significantly. This improvement correlated with a major modification in the anti-CD3 pattern of cytokine release. At the 90-min blood withdrawal time point cytokine serum levels showed a 100% decrease for IFN gamma, an 88% decrease for IL-6, and 85% decrease for IL-2, and a 75% decrease for TNF. At 4 hr IL-2 serum levels were diminished by 65%; IL-6, IL-3, and IFN gamma serum levels were comparable to controls; and, interestingly, TNF was still detected, whereas it has already disappeared when 145 2C11 was administered alone. Importantly, when given more than 1 hr prior to anti-CD3 injection, corticosteroids were ineffective. To conclude, high doses of corticosteroids must be given with a precise kinetics--i.e. 1 hr prior to anti-CD3 MoAb--to achieve their maximal beneficial effect in the prevention of the anti-CD3 reaction.
Similar articles
- Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.
Ferran C, Dy M, Sheehan K, Merite S, Schreiber R, Landais P, Grau G, Bluestone J, Bach JF, Chatenoud L. Ferran C, et al. Clin Exp Immunol. 1991 Dec;86(3):537-43. doi: 10.1111/j.1365-2249.1991.tb02966.x. Clin Exp Immunol. 1991. PMID: 1721015 Free PMC article. - Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway.
Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, Bluestone J, Bach JF, Chatenoud L. Ferran C, et al. Eur J Immunol. 1991 Oct;21(10):2349-53. doi: 10.1002/eji.1830211009. Eur J Immunol. 1991. PMID: 1833202 - Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.
Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach JF, et al. Ferran C, et al. Eur J Immunol. 1990 Mar;20(3):509-15. doi: 10.1002/eji.1830200308. Eur J Immunol. 1990. PMID: 2138557 - Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome.
Alegre ML, Gastaldello K, Abramowicz D, Kinnaert P, Vereerstraeten P, De Pauw L, Vandenabeele P, Moser M, Leo O, Goldman M. Alegre ML, et al. Transplantation. 1991 Oct;52(4):674-9. doi: 10.1097/00007890-199110000-00018. Transplantation. 1991. PMID: 1833865 - The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.
Chatenoud L, Ferran C, Bach JF. Chatenoud L, et al. Curr Top Microbiol Immunol. 1991;174:121-34. doi: 10.1007/978-3-642-50998-8_9. Curr Top Microbiol Immunol. 1991. PMID: 1839376 Review. No abstract available.
Cited by
- Contributions of Myosin Light Chain Kinase to Regulation of Epithelial Paracellular Permeability and Mucosal Homeostasis.
He WQ, Wang J, Sheng JY, Zha JM, Graham WV, Turner JR. He WQ, et al. Int J Mol Sci. 2020 Feb 3;21(3):993. doi: 10.3390/ijms21030993. Int J Mol Sci. 2020. PMID: 32028590 Free PMC article. Review. - Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.
Ilan Y, Shailubhai K, Sanyal A. Ilan Y, et al. Clin Exp Immunol. 2018 Sep;193(3):275-283. doi: 10.1111/cei.13159. Clin Exp Immunol. 2018. PMID: 29920654 Free PMC article. Review. - Beyond Ussing's chambers: contemporary thoughts on integration of transepithelial transport.
Herrmann JR, Turner JR. Herrmann JR, et al. Am J Physiol Cell Physiol. 2016 Mar 15;310(6):C423-31. doi: 10.1152/ajpcell.00348.2015. Epub 2015 Dec 23. Am J Physiol Cell Physiol. 2016. PMID: 26702131 Free PMC article. Review. - Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
Chatenoud L. Chatenoud L. Nat Rev Endocrinol. 2010 Mar;6(3):149-57. doi: 10.1038/nrendo.2009.275. Nat Rev Endocrinol. 2010. PMID: 20173776 Review. - Antibody immunosuppressive therapy in solid-organ transplant: Part I.
Mahmud N, Klipa D, Ahsan N. Mahmud N, et al. MAbs. 2010 Mar-Apr;2(2):148-56. doi: 10.4161/mabs.2.2.11159. MAbs. 2010. PMID: 20150766 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical